1	Combining Transdiagnostic and Disorder-Level GWAS Enhances Precision of Psychiatric
2	Genetic Risk Profiles in a Multi-Ancestry Sample
3	
4	Yousef Khan <sup>1</sup> *, Christal N. Davis <sup>1,2</sup> *, Zeal Jinwala <sup>1</sup> , Kyra L. Feuer <sup>1</sup> , Sylvanus Toikumo <sup>1,2</sup> ,
5	Emily E. Hartwell <sup>1,2</sup> , Sandra Sanchez-Roige <sup>3,4,5</sup> , Roseann E. Peterson <sup>6</sup> , Alexander S. Hatoum <sup>7</sup> ,
6	Henry R. Kranzler <sup>1,2</sup> , Rachel L. Kember <sup>1,2</sup>
7	
8 9	<sup>1</sup> Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104
10 11	<sup>2</sup> Mental Illness Research, Education and Clinical Center, Crescenz VAMC, Philadelphia, PA 19104
12 13	<sup>3</sup> Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, United States
14 15	<sup>4</sup> Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN 37235, United States
16 17 18 19 20 21	<ul> <li><sup>5</sup> Genomic Medicine, University of California San Diego, La Jolla, CA, USA</li> <li><sup>6</sup> Institute for Department of Psychiatry and Behavioral Sciences, Institute for Genomics in Health, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, United States</li> <li><sup>7</sup> Department of Psychological &amp; Brain Sciences, Washington University in St. Louis, St. Louis, MO 63130, United States</li> <li>* Authors made equal contributions.</li> </ul>
22	
23 24 25	Corresponding Author: Rachel L. Kember, PhD, 3535 Market Street, Suite 500, Philadelphia, PA 19104. Email: <u>rkember@pennmedicine.upenn.edu</u>
26 27 28 29 30 31 32 33 34 35	Dr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator- initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; and a holder of U.S. patent 10,900,082 titled: "Genotype-guided dosing of opioid agonists," issued 26 January 2021.

$\mathbf{r}$	c
.5	n
-	-

#### Abstract

37	The etiology of substance use disorders (SUDs) and psychiatric disorders reflects a
38	combination of both transdiagnostic (i.e., common) and disorder-level (i.e., independent) genetic
39	risk factors. We applied genomic structural equation modeling to examine these genetic factors
40	across SUDs, psychotic, mood, and anxiety disorders using genome-wide association studies
41	(GWAS) of European- (EUR) and African-ancestry (AFR) individuals. In EUR individuals,
42	transdiagnostic genetic factors represented SUDs (143 lead single nucleotide polymorphisms
43	[SNPs]), psychotic (162 lead SNPs), and mood/anxiety disorders (112 lead SNPs). We identified
44	two novel SNPs for mood/anxiety disorders that have probable regulatory roles on FOXP1,
45	NECTIN3, and BTLA genes. In AFR individuals, genetic factors represented SUDs (1 lead SNP)
46	and psychiatric disorders (no significant SNPs). The SUD factor lead SNP, although previously
47	significant in EUR- and cross-ancestry GWAS, is a novel finding in AFR individuals. Shared
48	genetic variance accounted for overlap between SUDs and their psychiatric comorbidities, with
49	second-order GWAS identifying up to 12 SNPs not significantly associated with either first-order
50	factor in EUR individuals. Finally, common and independent genetic effects showed different
51	associations with psychiatric, sociodemographic, and medical phenotypes. For example, the
52	independent components of schizophrenia and bipolar disorder had distinct associations with
53	affective and risk-taking behaviors, and phenome-wide association studies identified medical
54	conditions associated with tobacco use disorder independent of the broader SUDs factor. Thus,
55	combining transdiagnostic and disorder-level genetic approaches can improve our understanding
56	of co-occurring conditions and increase the specificity of genetic discovery, which is critical for
57	psychiatric disorders that demonstrate considerable symptom and etiological overlap.

58

#### Introduction

59	Substance use disorders (SUDs) commonly co-occur with mood, anxiety, and psychotic
60	disorders. <sup>1-3</sup> For example, about one-quarter of individuals with major depressive disorder
61	(MDD) meet criteria for at least one SUD, <sup>1</sup> and 20-80% of individuals seeking SUD treatment
62	have MDD. <sup>4</sup> Similarly, the prevalence of anxiety disorders among individuals with an illicit SUD
63	is almost three times that of the general population. <sup>2</sup> Additionally, nearly half (42%) of
64	individuals experiencing a first episode of psychosis <sup>5</sup> and a third of those with bipolar disorder <sup>3</sup>
65	(BD) have a co-occurring SUD. Such comorbidity complicates the clinical course of affected
66	individuals, resulting in greater healthcare and other costs. <sup>6,7</sup>
67	Large-scale genome-wide association studies (GWAS) <sup>8-15</sup> have shown these disorders to
68	be highly polygenic, with individual variants exerting a small influence on risk. These studies
69	also provide evidence of pleiotropy, whereby variants are associated with more than one
70	psychiatric trait. These pleiotropic effects partially account for the co-occurrence of psychiatric
71	traits and disorders. <sup>8-15</sup> Genomic structural equation modeling (gSEM) can leverage this shared
72	liability to identify common genetic factors that underlie multiple disorders. <sup>16</sup> In combination
73	with downstream analyses, these multivariate genetic approaches can improve our understanding
74	of the etiology of commonly co-occurring conditions by identifying shared biological pathways
75	and possible risk mechanisms.
76	Several gSEM studies have modeled pleiotropy across psychiatric disorders in European-

ancestry (EUR) individuals. The first modeled shared genetic variance across schizophrenia
(SCZ), BD, MDD, posttraumatic stress disorder (PTSD), and anxiety, identifying a single
common factor.<sup>16</sup> Across eight psychiatric disorders—attention-deficit hyperactivity disorder,
anorexia nervosa, autism spectrum disorder, BD, MDD, obsessive compulsive disorder, SCZ,

81	and Tourette syndrome <sup>17</sup> -three underlying genetic factors representing mood and psychotic
82	disorders, early-onset neurodevelopmental disorders, and compulsive disorders-best
83	represented the data. More recent work expanded this model by adding problematic alcohol use,
84	anxiety disorders, and PTSD, <sup>18</sup> which resulted in the previously combined mood and psychotic
85	disorders factor splitting into separate internalizing and psychotic factors.
86	Similarly, an addiction factor has been identified that underlies cannabis use disorder
87	(CanUD), opioid use disorder (OUD), and measures of problematic alcohol and tobacco use. <sup>19</sup>
88	Although this study included African-ancestry (AFR) in addition to EUR individuals, limited
89	power precluded the application of gSEM in AFR individuals. Instead, an alternative approach,
90	ASSET, <sup>20</sup> was taken to identify pleiotropic effects among AFR individuals. However, this
91	approach failed to identify any variants having effects common to all four substance use
92	behaviors in AFR individuals. Other research applying gSEM has derived a common factor
93	underlying measures of substance use in EUR individuals, <sup>21</sup> reaffirming the shared genetic basis
94	underlying multiple substance use behaviors or disorders.
95	Although research has demonstrated consistency in the genetic factor structure across
96	models of substance use and psychiatric disorders, these studies have applied gSEM only in EUR
97	individuals. The modeling of complex genetic relationships via structural equation modeling
98	imposes greater demands for statistical power than simpler univariate GWAS analyses, which
99	themselves are often underpowered in AFR and other non-EUR ancestry groups. Thus, the
100	statistical power requirements of the approach, whose strength lies in its ability to enhance our
101	understanding of the complexity of genetic relations, have hampered its application in non-EUR
102	ancestries.

103 Previous studies have also typically focused on identifying transdiagnostic genetic risk, 104 but gSEM can also enable more precise identification of disorder-specific genetic mechanisms 105 than individual GWAS. In combination with transdiagnostic genetic approaches, GWAS-bysubtraction<sup>22</sup> can parse associations with single nucleotide polymorphisms (SNPs) into those that 106 107 influence risk for a disorder through a common genetic factor from those that operate 108 independently of the common factor. The two resulting genetic dimensions can be used to 109 differentiate the associations of a common genetic factor with psychiatric, medical, and social 110 phenotypes from the associations of genetic risk that operates independently of the common 111 factor. Combining transdiagnostic and disorder-level approaches enhances statistical power to detect pleiotropic effects, while identifying patterns of genetic heterogeneity and increasing the 112 specificity of SNP discovery.<sup>23</sup> 113

114 To extend previous study findings, we used gSEM to characterize the underlying genetic 115 structure of SUDs, psychotic, and mood and anxiety disorders in EUR and AFR individuals. 116 First, we examined the genetic factor structure of the disorders using exploratory and 117 confirmatory factor analyses, and then we explored each factor's biological underpinnings by 118 conducting GWAS. Next, we investigated the shared genetic comorbidity of SUDs with 119 psychotic, mood, and anxiety disorders using a second-order gSEM approach, which involves 120 examining the relationships between the lower-level factors to identify genetic risks that are 121 shared across factors. Finally, we characterized the common and independent genetic variance 122 for select disorders using GWAS-by-subtraction. Thus, we sought to address two critical gaps in 123 previous research: first, by applying gSEM among AFR individuals, and second, by employing a hierarchical approach to explore both genetic specificity and transdiagnostic genetic risk. 124

125	Ultimately, these techniques were applied to obtain a more comprehensive understanding of the
126	genetic underpinnings of SUDs, psychotic, mood, and anxiety disorders.
127	Methods
128	To explore the genetic relationships among SUDs, psychotic, mood, and anxiety
129	disorders, we used gSEM, which is a statistical technique that integrates summary-level genetic
130	data with structural equation modeling. By estimating the genetic covariance structure among
131	traits, gSEM enables the explicit and flexible modeling of complex relationships. <sup>16</sup>
132	[Figure 1 here]
133	Summary Statistics
134	We used large discovery GWAS for SUDs, psychotic, mood, and anxiety disorders in
135	EUR and AFR individuals (Supplementary Tables 1-4) as inputs for gSEM. Genetic ancestry was
136	determined for each input GWAS by the researchers conducting the original study, and these
137	inferences should not be considered proxies for either race or ethnicity. Instead, the groups
138	represent statistical determinations of ancestral similarity, within which there remains
139	heterogeneity. The traits included four SUDs: alcohol use disorder (AUD), <sup>13,24</sup> tobacco use
140	disorder (TUD), <sup>15</sup> cannabis use disorder (CanUD), <sup>12</sup> and opioid use disorder (OUD); <sup>11</sup> two
141	disorders that can include psychotic features: BD <sup>10,25</sup> and SCZ; <sup>9,25</sup> and two mood and anxiety
142	traits: anxiety (ANX) <sup>8,26,27</sup> and MDD. <sup>14,28</sup> In EUR individuals, we used multi-trait analysis of
143	GWAS (MTAG) <sup>29</sup> to enhance the power to detect effects associated with a broad spectrum of
144	anxiety disorders, including generalized anxiety disorder, panic disorder, social phobia,
145	agoraphobia, and specific phobias (see Supplementary Materials and Supplementary Table 5).
146	The resulting ANX summary statistics produced by MTAG were then used as an input for gSEM.
147	[Table 1 here]

148	Prior to common factor modeling in accordance with the procedure for performing
149	gSEM, we calculated genetic correlations between the disorders using linkage disequilibrium
150	score regression (LDSC) implemented in GenomicSEM 0.0.5c. <sup>16</sup> To prevent downward bias in
151	LDSC estimates, when SNP-level sample sizes were not available within each set of summary
152	statistics, we calculated the effective sample size using the sum of effective sample sizes across
153	the input GWAS cohorts (see Supplementary Materials). <sup>30</sup> For EUR analyses, SNPs were
154	restricted to those contained within the EUR HapMap3 reference panel <sup>31</sup> with a minor allele
155	frequency $(MAF) > 0.01$ . We then performed LDSC using EUR 1000 Genomes Phase 3 linkage
156	disequilibrium (LD) scores. <sup>32</sup> Given the statistical challenges associated with including non-EUR
157	individuals in gSEM analyses due in part to differences in LD structure and admixture, we
158	compared the performance of three sets of LD scores before performing LDSC in AFR
159	individuals. We restricted each set of LD scores to well-imputed SNPs with $MAF > 0.01$ and
160	then compared several parameters, including LD score distribution, LD block length, and the
161	stability of SNP-based heritability and genetic correlation estimates to determine the optimal
162	approach (see Supplementary Materials). This step ensured the selection of an appropriately
163	matched reference panel to avoid biasing estimates. Ultimately, we selected the Pan-UKB AFR
164	reference data, <sup>33</sup> which enabled the best performance of gSEM models among AFR individuals.

165 Genomic Structural Equation Modeling

166 Consistent with best approaches for gSEM, we performed exploratory factor analysis 167 (EFA) and confirmatory factor analysis (CFA) on independent data to evaluate the reliability of 168 our results. We first performed EFA on the odd chromosomes using LDSC matrices derived from 169 the summary statistics of the previously described SUDs and psychiatric disorders to evaluate the 170 optimal number of factors and the loadings of each disorder in a hypothesis-free manner. We

used the *Matrix* R package to correct for the possibility of a non-positive definite matrix<sup>34</sup> within 171 172 the LDSC output and then performed EFA for 1-4 latent factors using the lavaan R package and a promax rotation.<sup>35</sup> Following EFA, we examined model fit indices (i.e., chi-square value, 173 174 Akaike information criterion (AIC), comparative fix index (CFI), and standardized root mean squared residual (SRMR)) and eigenvalues to determine the optimal model.<sup>36</sup> Traits with a 175 176 loading  $\geq 0.35$  on each latent factor were retained for confirmatory factor analysis (CFA), which 177 was performed on the even chromosomes to avoid overfitting the data. Because of the limited 178 statistical power in AFR models, factor analyses were performed on all chromosomes. 179 Following CFA, we prepared the input summary statistics for GWAS by standardizing 180 coefficients and standard error (SE) values, such that SNP effects were scaled similarly for 181 binary and continuous phenotypes. For quality control, we included only SNPs with MAF>0.01 182 and imputation score>0.60. In GWAS, we regressed each SNP on each latent variable using 183 diagonally weighted least squares (DWLS) estimation and standard genomic control. We 184 calculated the effective sample size of each resulting common factor GWAS as described by 185 Mallard et al. (2022).<sup>37</sup> 186 Next, we constructed second-order common factor models to capture genetic effects that

186 Next, we constructed second-order common factor models to capture genetic effects that
 account for co-occurrence among SUDs and their psychiatric comorbidities. For both the EUR
 and AFR analyses, to ensure identification of the second-order models, we set the loadings of
 each first-order factor onto its respective second-order factor equal to the square root of their
 genetic correlation.<sup>38</sup> We then ran GWAS on each second-order factor using the procedure
 described for the first-order common factor GWAS.

To identify significant independent SNPs from GWAS, we performed LD clumping with
 PLINK 1.9<sup>39</sup> using an r<sup>2</sup> threshold of 0.1 and physical distance threshold of 3000 kb

(Supplementary Materials). For loci not previously significantly associated with a corresponding
SUD, psychotic, mood, or anxiety disorder (hereafter referred to as novel), we performed
PheWAS on the lead SNP to examine its associations across the phenomic spectrum using the
GWAS Atlas (Supplementary Materials).<sup>40</sup> Additionally, for any novel lead SNPs identified, we
used the LD-based Probabilistic Identification of Causal SNPs (PICS) v2.1.1 finemapping tool to
assess their potential as the most likely causal variant to be responsible for the observed
association in a given locus.

201 After performing each of the first- and second-order common factor GWAS, we calculated Q<sub>SNP</sub>, a measure of heterogeneity that tests the null hypothesis that a SNP's effects 202 203 operate entirely through a common factor. For example, a SNP that primarily influences SUDs 204 through its effects on a single disorder, like TUD, should violate the null hypothesis. To identify 205 SNPs with heterogeneous effects, we examined associations between each SNP and common 206 factor via a common pathway model. Then, separately for each factor, we fit an independent 207 pathway model in which the SNP predicted each of the factor's indicators. We performed a chi-208 square difference test on the two models (Supplementary Figure 1) and removed SNPs with p < 5x 10<sup>-8</sup> (Supplementary Tables 6-10) from the factor's summary statistics prior to conducting all 209 210 post-GWAS analyses.

#### 211 GWAS-by-Subtraction

To ensure that the GWAS-by-subtraction models were informative and adequately powered, we performed these analyses only on disorders with a standardized unexplained variance  $\geq 0.30$  in the first-order CFA. Following the paradigm of Demange et al. (2021),<sup>22</sup> we first specified two latent genetic factors. On the first factor, we loaded only the specific disorder of interest (i.e., depending on the model, TUD, BD, or SCZ), while on the other factor we loaded

217 the specific disorder *and* the other disorders included in its broader common factor. Then, we 218 imposed two constraints by setting to 0 the covariance between: (1) the disorder of interest and 219 all other disorders, and (2) the two latent genetic factors. Finally, to capture genetic effects on the 220 disorder that were not correlated with the common factor, we regressed each SNP on the latent 221 factor with a sole loading for the disorder of interest. To identify genetic effects on the disorder 222 of interest that operated through the common factor, each SNP was regressed on the latent factor 223 on which all common factor traits were loaded. Due to the limited statistical power of the AFR 224 models (max N<sub>eff</sub> = 6,421), we restricted GWAS-by-subtraction analyses to EUR models. The 225 effective sample size calculations for each of the GWAS-by-subtraction models were adjusted to account for the fact that the GWAS modeled residual heritability.<sup>22</sup> 226

227 Biological Characterization

228 We used Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) version 1.6.0<sup>41</sup> to conduct post-GWAS analyses of each GWAS (i.e., first-order 229 230 common factors in EUR and AFR individuals, second-order common factors in EUR and AFR 231 individuals, and GWAS-by-subtraction models in EUR individuals). Gene-based tests, gene-set 232 enrichment, and gene-tissue expression analyses were conducted using MAGMA version 1.08.42 We examined gene expression in BrainSpan<sup>43</sup> and GTEx v8<sup>44</sup> tissue samples. SNP-to-gene 233 234 associations and gene annotations were evaluated using: (1) expression quantitative trait loci (eQTLs) from PsychENCODE<sup>45</sup> and GTEx v8<sup>44</sup> brain tissue samples and (2) chromatin 235 interactions via Hi-C data for the dorsolateral prefrontal cortex, hippocampus, ventricles, and 236 237 neural progenitor cells.<sup>46</sup> To annotate the protein products and investigate protein-protein interactions of MAGMA-identified genes, we used the STRING database v12.0 and applied its 238 default parameters.<sup>47</sup> Enrichment of protein-protein interactions was calculated as the observed 239

number of edges (i.e., interactions) divided by the expected number of edges in the protein
network. Significant enrichment would suggest that the proteins that are encoded by genes

- associated with a factor participate in common pathways relevant to that factor.
- 243 Genetic Correlations with gSEM Factors

244 Genetic correlations between gSEM output summary statistics and other traits were calculated using LDSC<sup>48,49</sup> with 1000 Genomes Project phase 3<sup>32</sup> (for EUR) and PanUKB<sup>33</sup> (for 245 246 AFR) data as LD references. For first- and second-order common factors in EUR individuals, we used the Complex-Traits Genetics Virtual Lab<sup>50</sup> to calculate batch genetic correlations with 1.437 247 248 traits across a wide variety of domains assessed via International Classification of Diseases 249 (ICD) codes and self-report. In AFR individuals, genetic correlations were calculated for selected 250 psychiatric and medical phenotypes as the Complex-Traits Genetics Virtual Lab does not 251 currently facilitate LDSC in non-EUR ancestries. For GWAS-by-subtraction models in EUR 252 individuals, we calculated genetic correlations with a selection of relevant psychiatric, social, 253 and physical traits to facilitate comparison of the common and independent genetic effects 254 associated with each disorder. We applied a Benjamini-Hochberg false discovery rate (FDR) 255 correction to each set of genetic correlation analyses to account for multiple testing. Lastly, we 256 calculated trans-ancestry genetic correlations using the regression fit method to compare gSEM common factors across EUR and AFR ancestry individuals with Popcorn v1.0<sup>51</sup> and ancestry-257 matched 1000 Genomes reference files. Reference files were prepared by excluding the MHC 258 259 region, and Popcorn was used to compute LD scores for both populations.

260 Polygenic Score-Based PheWAS

Prior to calculating polygenic scores (PGS) in the Penn Medicine Biobank (PMBB),
GWAS for the first-order, second-order, and TUD GWAS-by-subtraction models were re-run

283	Results
282	significant associations.
281	PheWAS package <sup>56</sup> in R. We used a Benjamini-Hochberg FDR corrected p-value to ascertain
280	phecode from the PGS, with sex, age, and the top 10 PCs included as covariates using the
279	standardized, and PheWAS was conducted by fitting a logistic regression predicting each
278	individuals with at least two instances of a given ICD code ("phecodes"). PGS were
277	ICD-9 and ICD-10 codes were gathered from EHR and mapped to phecodes. Cases were
276	individuals and 29,355 EUR individuals for inclusion in the PheWAS.
275	principal components (PCs) using smartpca.54,55 These procedures resulted in 10,383 AFR
274	from analyses. Genetic ancestry was determined using quantitative discriminant analysis of
273	In the case of related individuals (pi-hat threshold $\geq 0.25$ ), one from each pair was removed
272	the Haplotype Reference Consortium panel) and Minimac4 on the TOPMed Imputation Server.
271	with sex discrepancies. Imputation was performed using Eagle2 (Reference-based phasing using
270	removing SNPs with marker call rates <95% and sample call rates <90%, as well as individuals
269	was performed using the Illumina Global Screening Array. Quality control procedures included
268	provide access to their electronic health record (EHR) and blood or tissue samples. <sup>53</sup> Genotyping
267	PMBB participants are recruited through the University of Pennsylvania Health System and
266	association between genetic variants and traits across the spectrum of human disease and health.
265	association study (PheWAS) in the PMBB. PheWAS is a hypothesis-free approach to explore the
264	from gSEM output summary statistics using PRS-CSx <sup>52</sup> and conducted a phenome-wide
263	excluding PMBB to ensure independence of the GWAS and target samples. We calculated PGS

284 Genetic Correlations among Input GWAS

285	<i>European Ancestry.</i> Genetic correlations among SUDs ranged from 0.60 (SE = $0.06$ , $p < 0.06$ )
286	0.001; TUD and OUD) to 0.92 (SE = 0.05, $p < 0.001$ ; AUD and OUD). MDD and ANX were
287	strongly genetically correlated ( $r_g = 0.91$ , SE = 0.04, $p < 0.001$ ), as were BD and SCZ ( $r_g = 0.68$ ,
288	SE = 0.03, $p < 0.001$ ). Furthermore, SUDs were significantly genetically correlated with the
289	other psychiatric disorders, ranging from 0.08 (SE = 0.02, $p < 0.001$ ; TUD and BD) to 0.51 (SE
290	= 0.03, $p < 0.001$ ; AUD and MDD; Supplementary Figure 2 and Supplementary Table 11).
291	African Ancestry. All four SUDs exhibited significant genetic correlations with one
292	another, ranging from 0.56 (SE = 0.10, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (SE = 0.18, $p < 0.001$ ; TUD and CanUD) to 0.89 (S
293	0.001; OUD and CanUD). MDD and ANX were significantly correlated ( $r_g = 0.89$ , SE = 0.385, p
294	= 0.021), as were BD and SCZ ( $r_g$ = 0.43, SE = 0.17, $p$ = 0.011). Across disorder classes, AUD
295	was correlated with all the psychiatric disorders except BD ( $r_g = 0.19$ , SE = 0.15, $p = 0.21$ ). On
296	the other hand, TUD was only significantly genetically correlated with BD ( $r_g = 0.24$ , SE = 0.12,
297	$p = 0.037$ ) and SCZ ( $r_g = 0.29$ , SE = 0.10, $p = 0.005$ ). CanUD was significantly genetically
298	correlated with all the psychiatric disorders except ANX ( $r_g = 0.29$ , SE = 0.20, $p = 0.145$ ), and
299	OUD was correlated with all (Supplementary Figure 3 and Supplementary Table 12).
300	First-Order Common Factors: SUDs, Psychotic, and Mood Disorders
301	European Ancestry. Of the EFA models examined, the 3-factor model fit the data best
302	(Supplementary Table 13). As all loadings were $\geq 0.35$ with no significant cross-loadings, all
303	traits were carried forward on their respective factors for CFA, which fit the data well ( $\chi^2(17) =$
304	$130.04, p = 1.84 \times 10^{-19}$ , AIC = 168.04, CFI = 0.95, SRMR = 0.05). All SUDs loaded onto the first
305	factor, while BD and SCZ loaded onto the second, and MDD and ANX onto the third. The
306	factors were significantly intercorrelated, ranging from 0.39 (F1~F2) to 0.50 (F2~F3)
307	(Supplementary Table 14).

n n n	
KI IX	

## [Figure 2 here]

309	The SUD factor GWAS identified 143 lead SNPs (Supplementary Table 15), of which 47
310	were not genome-wide significant (GWS) or in LD with any GWS SNPs in the input GWAS,
311	although they had all been significantly associated with SUDs or SUD-related traits in prior
312	GWAS (Supplementary Table 15).57 There were 17 independent Q-SNPs that demonstrated
313	significant heterogeneity across SUDs (Supplementary Table 6). The psychotic disorder factor
314	GWAS identified 9 independent Q-SNPs (Supplementary Table 7) and 162 lead SNPs
315	(Supplementary Table 16), 27 of which had not been identified by the SCZ or BD GWAS, but all
316	of which had previously been GWS or in LD with GWS SNPs in at least one psychotic trait
317	GWAS (Supplementary Table 16). The mood factor GWAS identified 14 independent Q-SNPs
318	(Supplementary Table 8) and 112 lead SNPs (Supplementary Table 17), 13 of which were not
319	identified by the MDD or ANX GWAS, and 2 of which (rs75174029 and rs7652704) were not
320	previously significantly associated with or in LD with GWS SNPs for any mood or anxiety
321	disorder (Supplementary Table 17). PheWAS in the GWAS Atlas identified associations of
322	rs75174029 with the number of non-cancer related illnesses, general risk tolerance, and having
323	recent trouble relaxing; and rs7652704 with sensitivity/hurt feelings, neuroticism, and positive
324	affect, among other related traits (Supplementary Figure 4).
325	rs75174029 is an intronic variant in FOXP1, which serves as a key regulatory gene in
326	neural development.58,59 Finemapping identified the SNP as the most likely causal variant
327	accounting for the observed association within the locus (PICS probability = $0.307$ ;
328	Supplementary Table 18). Additionally, Hi-C chromatin interaction data (Supplementary Figure
329	5) revealed that rs75174029 contacts several regions of FOXP1, including its promoter. Taken
330	together, this evidence suggests rs75174029's association with mood/anxiety disorders may be

331	due to its presence in an enhancer with cis-regulatory function on FOXP1 during neural
332	development. The second novel SNP, rs7652704 (Supplementary Figure 6), is an intronic variant
333	in an uncharacterized non-coding RNA locus. rs7652704 and 20 other SNPs in strong LD all had
334	PICS probabilities of 0.027, suggesting difficulty in determining the most likely causal variant
335	accounting for the association in the locus (Supplementary Table 19). rs7652704 is an eQTL of
336	NECTIN3 (also known as PVLR3) in cultured fibroblasts and displays chromatin interaction with
337	both <i>BTLA</i> , which is a gene involved in immune response, <sup>60</sup> and <i>NECTIN3</i> , which encodes a
338	nectin adhesion molecule that regulates cell organization and modulates stress responses. <sup>61-63</sup>
339	Thus, ample evidence associates both rs75174029 and rs7652704 with regulatory roles.
340	Gene-tissue expression analyses showed a role for both SUD- and psychotic disorder-
341	related genes during prenatal brain development (Supplementary Figures 7 and 8), but no
342	developmental period was significant for the mood disorders factor (Supplementary Figure 9).
343	Mapped genes from each of the factor GWAS were significantly enriched for protein-protein
344	interactions, indicating shared biological functions among disorders of the same class (SUDs =
345	1.37x, psychotic = 1.40x, and mood/anxiety disorders = 1.43x enrichment; $ps < 1.00 \times 10^{-16}$ ).
346	[Figure 3 here]
347	<i>African Ancestry.</i> Fit was generally poor for each of the EFA models (all CFIs < 0.40;
348	Supplementary Table 20). Upon examining each model's factor loadings, the proportion of
349	variance explained by each factor, and eigenvalues, we tested two CFA models: a 2-factor model
350	representing SUDs and psychiatric disorders and a 3-factor CFA model replicating the factor
351	structure identified in EUR individuals. Attempting to fit the 3-factor CFA led to a negative
352	residual variance and a correlation >1 between the psychotic and mood disorder factors. Because
353	negative variances and correlations that are out of bounds can indicate issues with model

354 misspecification or overfitting the data, we proceeded with the 2-factor CFA model, which had 355 an adequate fit  $(\gamma^2(19) = 21.49, p = 0.31, AIC = 55.49, CFI = 0.99, SRMR = 0.10)$  and required 356 no constraints (Figure 2 and Supplementary Table 21). The SUD factor GWAS (Supplementary Figure 10) identified 1 lead SNP, rs1944683, 357 358 positioned within an intergenic region on chromosome 11. To our knowledge, this variant has not 359 previously been GWS or in LD with any GWS SNPs in AFR GWAS of substance use traits. 360 However, the locus has been associated with alcohol consumption, tobacco-related traits, opioid use disorder, and cannabis use disorder in EUR and cross-ancestry studies.<sup>64-66</sup> The SNP 361 362 exhibited chromatin interaction with two genes: BLID and Cllorf63. A PheWAS of the lead SNP in the GWAS Atlas identified significant associations with regular smoking, past-month stomach 363 364 pain, and tobacco-related conditions, such as atrial fibrillation and respiratory function (i.e., 365 forced vital capacity and peak expiratory flow). One lead Q<sub>SNP</sub>, rs10489130, identified on 366 chromosome 4, exhibited significant associations with AUD only and was GWS in a previous 367 AUD GWAS in AFR individuals, suggesting that this SNP may display specificity for AUD 368 rather than influencing SUDs broadly.<sup>66</sup> For the SUD factor, gene expression was significantly enriched in brain tissues involved 369 370 in emotion processing, reward signaling, and cognitive control, including the putamen, 371 amygdala, caudate, and hippocampus (Supplementary Figure 11). No significant variants were 372 identified for the psychiatric disorders factor (Supplementary Figure 12). Gene expression was 373 also not significantly enriched for any developmental stage or tissue type, although the top 374 associations were with brain tissues (Supplementary Figure 13). 375 **Second-Order Common Factors** 

376	European Ancestry. The SUD factor was significantly genetically correlated with both
377	the psychotic ( $r_g = 0.38$ , SE = 0.03, $p < 0.001$ ) and mood ( $r_g = 0.44$ , SE = 0.03, $p < 0.001$ )
378	disorder factors. We used a higher-order CFA model ( $\chi^2(2) = 57.61$ , $p = 3.09 \times 10^{-13}$ , AIC = 65.61,
379	CFI = 0.91, $SRMR = 0.07$ ; Supplementary Figure 14 and Supplementary Table 22) to examine
380	this shared genetic structure. After accounting for shared genetic risk, there was less standardized
381	residual variance in the SUD factor ( $u_{SUD} = 0.19$ , SE = 0.04) than the psychotic ( $u_{Psychotic} = 0.63$ ,
382	SE = 0.05) or mood disorder factors ( $u_{Mood}$ = 0.56, SE = 0.04). A GWAS of the SUD and
383	psychotic disorders factor identified 4 independent Q-SNPs (Supplementary Table 9) and 76 lead
384	SNPs (Supplementary Table 23 and Supplementary Figure 15), 12 of which were not significant
385	in any input or the first-order GWAS. For the SUD and mood factor, 6 independent Q-SNPs
386	(Supplementary Table 10) and 62 lead SNPs were identified (Supplementary Table 24 and
387	Supplementary Figure 16), 5 of which were in loci that were not significant in any input or first-
388	order GWAS. All lead SNPs at the second-order level were previously associated with related
389	traits.

390 Genetic risk shared among SUD and psychotic disorders implicated several gene sets, 391 including molecular functions such as transcription regulation and sequence-specific DNA 392 binding, and biological processes such as neuron differentiation. Genetic risk shared between 393 SUDs and mood disorders was associated with enrichment in two gene sets involved in the 394 biological processes of mechanosensory behavior and axonal protein transport. For both second-395 order factors, gene expression was enriched in brain tissues (Supplementary Figures 17 and 18). Genes associated with both second-order factors were significantly enriched for protein-protein 396 397 interactions (SUDs and psychotic disorder = 1.54x, SUDs and mood/anxiety disorders = 1.57x;  $ps < 1.00 \ge 10^{-16}$ ). 398

399	African Ancestry. The SUD and psychiatric disorder factors were highly genetically
400	correlated ( $r_g = 0.74$ , SE = 0.13, $p < 0.001$ ), and a second-order CFA model accounting for this
401	shared genetic risk fit the data well ( $\chi^2(19) = 21.49$ , $p = 0.31$ , AIC = 55.49, CFI = 0.99, SRMR =
402	0.10; Supplementary Table 25 and Supplementary Figure 19). Although no significant SNPs
403	were identified by the second-order GWAS (Supplementary Figure 20), there was enriched gene
404	expression in several brain regions, including those associated with reward processing (putamen,
405	caudate, nucleus accumbens), emotion processing and memory (amygdala, hippocampus), and
406	executive functions and decision-making (anterior cingulate cortex; Supplementary Figure 21).
407	GWAS-by-Subtraction
408	Common and independent genetic effects were examined for TUD, SCZ, and BD, which
409	each had a residual variance $\geq 0.30$ in the EUR first-order common factor models. We chose this
410	threshold because analyses performed on traits with less residual variance were underpowered
411	for parsing transdiagnostic from disorder-level effects. We identified 102 GWS lead SNPs for
412	TUD Common, which represented genetic effects on TUD that operate through the SUD factor.
413	There were 20 lead SNPs for TUD Independent, which represented genetic effects on TUD that
414	are not shared with the other three SUDs. 13 of these SNPs did not reach significance in the TUD
415	Common GWAS (Supplementary Table 26). Chromatin interaction mapping identified several of
416	the nicotinic acetylcholine receptor genes (CHRNA2, CHRNA4, and CHRNA5; Supplementary
417	Figure 22). Gene-set analyses for TUD Independent implicated genes involved in nicotinic
418	acetylcholine reception and behavioral responses to nicotine.
419	We identified 51 lead SNPs for SCZ Common and 18 for SCZ Independent, of which 15
420	were not GWS nor in LD with GWS SNPs in the SCZ Common GWAS (Supplementary Table
421	27). Chromatin interaction mapping identified several genes on chromosome 6, including the

422 ZSCAN and HIST1H gene families, as possible sources of functional effects related to SCZ risk

- 423 independent of BD (Supplementary Figure 23). Although after Bonferroni correction no gene-
- 424 sets were significantly enriched for SCZ Independent, the top set involved up-regulated genes in
- 425 the prefrontal cortex in mouse models of 22q11.2 microdeletions, which, in humans, are
- 426 associated with risk of developing SCZ.<sup>67</sup> Finally, there were 189 significant lead SNPs for BD
- 427 Common and 13 for BD Independent, 10 of which did not reach significance in the BD Common
- 428 GWAS (Supplementary Table 28). Although few SNPs were significant in the BD Independent
- 429 GWAS, chromatin interactions identified potential functional effects of these variants on genes,
- 430 including *MXII*<sup>68</sup> and *ADD3*,<sup>69</sup> which have been previously associated with BD (Supplementary
- 431 Figure 24). For BD Independent, one gene-set involved in the regulation of trans-synaptic
- 432 signaling remained significant after Bonferroni correction. Protein-protein interactions were
- 433 significantly enriched for TUD, SCZ, and BIP Independent (TUD = 3.31x,  $p = 3.45 \times 10^{-13}$ , SCZ
- 434 = 5.48x,  $p < 1.00 \text{ x } 10^{-16}$ , BIP = 5.75x,  $p = 2.19 \text{ x } 10^{-11}$ ), indicating potential molecular
- 435 mechanisms with enhanced specificity (Supplementary Figures 25-27).
- 436

#### [Figure 4 here]

437 Genetic Correlations with gSEM Factors

*European Ancestry.* The SUD factor was, as expected, strongly genetically correlated with smoking and alcohol traits, as well as depression and socioeconomic factors, including reduced educational attainment, unemployment due to sickness/disability, and the Townsend deprivation index (Supplementary Figure 28). The psychotic factor correlated most strongly with related traits, such as SCZ, BD, depression, and anxiety. However, psychotic disorders also exhibited a positive genetic correlation with risk taking and a negative correlation with cognitive performance, which consists of fluid intelligence and the first principal component of scores on

445 neuropsychological tests (Supplementary Figure 29). Although the mood disorders factor 446 correlated most strongly with measures of depression and anxiety, the remaining correlations 447 were predominantly with somatic conditions, such as chronic pain, longstanding 448 illness/disability/infirmity, and prescription medication usage (Supplementary Figure 30). For the second-order factors, the top genetic correlations were a mixture of SUD-related, 449 450 psychiatric, and medical traits. The SUD and psychotic disorders factor, for example, correlated 451 most strongly with SCZ and BD. Other significant genetic correlations included smoking-related 452 traits, cognitive measures, and risk taking, as with the first-order psychotic disorder factor. The 453 SUD and mood disorders factor correlated most strongly with mood and anxiety traits and illness and medication use for pain or gastrointestinal problems, reflecting similar associations observed 454 455 for the first-order mood disorders factor (Figure 5). 456 Genetic correlations underscored differences between disorder-level and transdiagnostic genetic effects (Figure 4). Although TUD Common was significantly positively genetically 457 correlated with SCZ ( $r_g = 0.35$ , SE = 0.02, p < 0.001), TUD Independent was not ( $r_g = -0.05$ , SE 458 459 = 0.03, p = 0.08), with a similar pattern observed for other thought/psychotic disorders. SCZ 460 Common had a nominally weaker negative genetic correlation with cognitive performance ( $r_g = -$ 0.09, SE = 0.02, p < 0.001) and was significantly positively correlated with educational 461 462 attainment ( $r_g = 0.11$ , SE = 0.02, p < 0.001), while SCZ Independent had consistently negative 463 associations with both ( $r_g = -0.22$ , SE = 0.03, p < 0.001 and  $r_g = -0.09$ , SE = 0.02, p < 0.001, 464 respectively). Among other traits, BD Common and Independent showed opposite patterns of 465 associations with automobile speeding propensity and cognitive performance, both of which were negative for BD Common ( $r_g$  = -0.21, SE = 0.02, p < 0.001; and  $r_g$  = -0.24, SE = 0.02, p < 0.02466 467 0.001, respectively) and positive for BD Independent ( $r_g = 0.13$ , SE = 0.03, p < 0.001; and  $r_g =$ 

468 0.05, SE = 0.02, p = 0.03, respectively). SCZ and BIP Independent had significantly different 469 associations with risk-taking ( $r_g = 0.25$ , SE = 0.03, p < 0.001 vs.  $r_g = -0.04$ , SE = 0.03, p = 0.14; 470 Z = 6.84,  $p = 8.18 \times 10^{-12}$ ) and MDD ( $r_g = 0.35$ , SE = 0.03, p < 0.001 vs.  $r_g = -0.04$ , SE = 0.03, p471 = 0.22; Z = 9.19,  $p = 3.84 \times 10^{-20}$ ).

African Ancestry. The psychiatric disorders factor was genetically correlated with all 11 472 473 traits examined, and the SUD factor was significantly correlated with all except PTSD. There 474 were minimal differences between the genetic correlations for the first-order factors, likely due 475 to the large variance in estimates resulting from low statistical power (Supplementary Figure 31). 476 The second-order SUD and psychiatric factor correlated significantly with all traits except 477 PTSD, and the strongest correlations were with smoking trajectory, OUD, depression, and 478 maximum alcohol consumption (Supplementary Figure 32). 479 Trans-ancestry. The EUR SUD factor was significantly genetically correlated with the

480 AFR SUD factor ( $r_g = 0.730$ , SE = 0.094, p = 0.004). Similarly, the AFR psychiatric disorders 481 factor was genetically correlated with both the EUR psychotic factor ( $r_g = 0.471$ , SE = 0.216, p =482 0.014) and the EUR mood disorders factor ( $r_g = 0.571$ , SE = 0.204, p = 0.035).

483

#### [Figure 5 here]

484 PheWAS in Penn Medicine BioBank

*European Ancestry.* Among participants in PMBB, the SUD factor was associated with
TUD, tobacco-related illnesses (lung and other respiratory system cancers and chronic airway
obstruction), and mood/anxiety disorders (Supplementary Figure 33 and Supplementary Table
29). The psychotic disorders factor was significantly associated only with psychiatric traits,
including BD and mood/anxiety disorders (Supplementary Figure 34 and Supplementary Table
30). In contrast, although the mood disorders factor was most strongly associated with the

491 presence of various mood and anxiety disorders, it was also associated with physical health
492 conditions like pain, sleep disorders, and obesity (Supplementary Figure 35 and Supplementary
493 Table 31).

The second-order SUD and psychotic disorders factor was significantly associated with tobacco and alcohol-related disorders, with a nonsignificant association with BD (Supplementary Figure 36 and Supplementary Table 32). Although the PheWAS of the SUD and mood disorders factor revealed the strongest associations with substance use and psychiatric disorders, it also showed significant associations with pain, type 2 diabetes, ischemic heart disease, hypertension, and sleep disorders, amongst other physical health conditions (Supplementary Figure 37 and Supplementary Table 33).

501 PheWAS further highlighted the enhanced specificity of the GWAS-by-subtraction 502 models. Although the TUD Common factor was associated with multiple SUDs, the TUD 503 Independent factor demonstrated greater specificity, having the highest associations with TUD 504 and related medical conditions, such as chronic airway obstruction (Supplementary Figure 38). 505 PheWAS for SCZ Common factor showed broad associations with mood disorders, including 506 BD, but there were no significant associations for SCZ Independent (Supplementary Figure 39). 507 PheWAS of both the BD Common and Independent PRS showed significant associations with 508 BD and other mood disorders, but the association with depression was only significant for BD 509 Independent (Supplementary Figure 40).

*African Ancestry.* Although there were no statistically significant phenotypic associations
among AFR individuals in PMBB, the top hits generally aligned with the factor being examined.
For example, the SUD factor was most strongly associated with TUD, followed by SUDs
broadly (Supplementary Figure 41 and Supplementary Table 34). Among the top associations for

the psychiatric factor were generalized anxiety disorder and the "other mental disorder"
phenotype (Supplementary Figure 42 and Supplementary Table 35). Similar results were seen for
the second-order SUD and psychiatric factor, which included TUD, alcohol-related disorders,
and mood disorders within the top associations (Supplementary Figure 43 and Supplementary
Table 36).

519

#### Discussion

520 Leveraging the largest available GWAS in European- and African-ancestry individuals, 521 we combined complementary multivariate methodologies to examine the shared genetic 522 architecture across SUDs, psychotic, mood, and anxiety disorders. We also examined genetic 523 effects that operate independent of the shared genetic risk to influence disorders. By integrating 524 transdiagnostic and disorder-level gSEM, we identified potential biological mechanisms that 525 contribute to comorbidity across disorder classes and those that distinguish commonly co-526 occurring conditions. Our findings revealed both pervasive pleiotropy across SUDs and other 527 psychiatric disorders and trait-specific associations, while also highlighting the need to increase 528 representation of non-European ancestry individuals in genetic studies of mental health.

#### 529 Identification of SUDs, Psychotic, and Mood Disorder Factors

530 Consistent with other psychiatric genetic findings,<sup>19,70</sup> we identified common genetic 531 factors underlying disorders that exhibit shared features. As expected, MDD and anxiety, which 532 are highly comorbid and share similar symptoms, loaded onto the same factor. Additionally, 533 across ancestries, common genetic risk partially accounted for the shared features of BD and 534 SCZ. Other gSEM studies have also showed that SCZ and BD load onto the same genetic 535 factor,<sup>18,70-72</sup> highlighting their strong shared etiology despite belonging to different diagnostic 536 classes. Although smaller samples and greater genetic diversity limited statistical power to

replicate the EUR factor structure in AFR individuals, there were significant commonalities
across genetic ancestry groups. For example, in both AFR and EUR models, SUDs loaded onto a
single factor that was highly genetically correlated with a previously identified genetic addiction
factor.<sup>19</sup> Additionally, trans-ancestry genetic correlations highlighted the consistency of the
genetic influences on the AFR psychiatric disorders factor with both the EUR psychotic and
mood disorders factors.

543 In AFR individuals, we identified a lead SNP (rs1944683) associated with SUDs that had 544 not been previously GWS or in LD with GWS SNPs in AFR substance-related GWAS. This 545 locus has, however, been previously implicated in alcohol, tobacco, cannabis, and opioid-related traits in EUR and cross-ancestry GWAS.<sup>64-66</sup> Our ability to identify this lead SNP was facilitated 546 547 by the use of gSEM, which allowed us to leverage power across multiple SUDs. In doing so, we 548 were able to overcome some of the limitations posed by the relatively low statistical power of 549 existing GWAS in AFR populations. However, despite statistical advancements, our study 550 remained underpowered in AFR individuals.

551 In EUR individuals, we detected two significant loci for the mood and anxiety disorders 552 factor that had not been previously significant in GWAS of mood or anxiety disorders. 553 Performing chromatin interaction mapping on the lead SNPs for these loci implicated genes 554 involved in immune and stress responses (BTLA and NECTIN3, respectively) and a gene related to hippocampal development (FOXP1).<sup>58,60,62,73</sup> The identification of BTLA, which encodes the 555 556 B- and T-lymphocyte attenuator protein, is consistent with other research highlighting the role of immune dysregulation in psychiatric pathogenesis.74-76 NECTIN3 encodes a cell adhesion 557 558 molecule that is involved in synaptic plasticity, enriched in hippocampal neurons, and implicated in stress-related disorders.<sup>61,62,77</sup> FOXP1, a transcription factor that plays a crucial role in 559

hippocampal development, has also been implicated in the regulation of synaptic plasticity.<sup>58</sup>
Further highlighting the potential role of immune functioning, these loci have previously been
implicated in GWAS of lymphocyte and leukocyte counts, as well as autoimmune conditions,
such as inflammatory bowel disease. Thus, dysfunctions in synaptic plasticity and immune
regulation may underlie a range of psychiatric conditions, including MDD and anxiety.<sup>78,79</sup>
Targeting these common biological pathways could lead to the development of therapeutics with
broader efficacy profiles.

567 In EUR individuals, both the SUD and psychotic disorder factors showed a significant 568 association with genes expressed in brain tissue during prenatal development. Although no 569 developmental stage reached significance for mood disorders or in AFR individuals, the top 570 associations were consistently prenatal periods. This underscores the importance of early 571 neurodevelopmental processes, including neurogenesis, synaptogenesis, and the formation of 572 neurotransmitter systems, in shaping the susceptibility to SUDs and psychiatric disorders. 573 Furthermore, prenatal development may represent a sensitive window during which genetic and 574 environmental factors interact to influence long-term mental health outcomes.<sup>80</sup> Epigenetic mechanisms, such as those modulated by maternal stress and other environmental conditions,<sup>81,82</sup> 575 576 may play a crucial role in mediating gene expression patterns and contributing to the 577 developmental origins of psychiatric disorders. The specifics of these epigenetic mechanisms and 578 other non-coding regulatory processes remain largely unclear. However, statistical and 579 technological advances, such as next-generation sequencing and multi-omics analysis, show promise for furthering knowledge in this area.83 580

581 SUDs Share Genetic Liability with Psychotic and Mood Disorders

582 Evaluating shared genetic variance across the common factors revealed higher-order 583 dimensions of liability to psychopathology, including genetic risk shared between SUDs and 584 psychotic disorders and between SUDs and mood/anxiety disorders. A PheWAS in the PMBB 585 showed broad phenotypic manifestations of these dimensions of genetic liability. Notably, in EUR individuals, SUD and mood/anxiety disorders exhibited significant associations with 586 587 various physical health conditions, including obesity, type 2 diabetes, chronic pain, chronic 588 airway obstruction, heart disease, hypertension, and sleep disorders. Because the PheWAS was 589 underpowered in AFR individuals, there were no significant associations, though the top 590 associations included relevant phenotypes, such as alcohol-related disorders, TUD, and mood disorders. 591

592 Genetic correlations further underscored the pervasive impact of genetic risk for 593 psychiatric comorbidities and SUDs. The second-order factors (i.e., SUD and mood disorders 594 and SUD and psychotic disorders) were genetically correlated with adverse outcomes that 595 included lower cognitive performance, elevated HDL cholesterol, chronic pain, long-standing 596 illness, and miserableness. In AFR individuals, the second-order factor, representing shared 597 genetic effects across SUDs and psychiatric disorders, was significantly genetically correlated 598 with pain intensity and various substance use and psychiatric phenotypes. Thus, genetic risk for 599 co-occurring SUDs and psychiatric disorders has far-reaching implications for both mental and 600 physical health.

In addition to shared variance, in EUR individuals there was substantial unique genetic variance for both psychotic (0.63, SE = 0.05) and mood/anxiety disorders (0.56, SE = 0.04). The residual genetic variance in SUDs was also significant, albeit smaller, after accounting for genetic variance shared with psychotic and mood/anxiety disorders (0.19, SE = 0.04). In EUR

individuals, more of the genetic variance in SUDs was shared with mood/anxiety than psychotic
disorders. This suggests that there are different degrees of genetic convergence between SUDs
and their common psychiatric comorbidities. Evaluating these patterns of genetic overlap and
heterogeneity can help distinguish highly comorbid psychiatric disorders and pinpoint both
shared and distinct etiological mechanisms.

# 610 Specificity of Genetic Effects for Tobacco Use Disorder, Schizophrenia, and Bipolar 611 Disorder

612 To evaluate transdiagnostic and disorder-level liability, SNPs for TUD, SCZ, and BD 613 were parsed into effects that: (1) operated through their respective common factors or (2) were 614 uncorrelated with the common factor. Thus, we were able to distinguish biological mechanisms 615 and genetic correlates that contribute to comorbidity across disorders from those that show greater specificity. This hierarchical approach can yield genetic knowledge across levels of 616 psychopathology and identify patterns of convergence and divergence across disorders. 617 618 As an example of the utility of this approach, GWAS-by-subtraction findings provided 619 insights into the underlying structure of psychotic disorders. SCZ and BD shared a common 620 genetic core, consistent with their shared psychotic features and in line with empirical nosological models.<sup>84</sup> However, the genetic risk for each disorder that was independent of this 621 622 common psychotic core showed different patterns of associations with other complex traits. For 623 example, SCZ Independent was more negatively genetically correlated with measures of 624 cognition and educational attainment than BD Independent, which was more strongly associated 625 with risk-taking behaviors and affective disorders. Our results are highly consistent with the 626 expanded psychosis continuum hypothesis, which proposes that although SCZ and BD share a psychotic core, cognitive and affective domains differentiate the disorders.<sup>85</sup> Specifically, SCZ is 627

characterized by greater cognitive impairments and BD by greater affective impairments. Our
 findings lend genetic support to this hypothesis, previously investigated using only psychological
 and neural evidence.<sup>85</sup>

631 PheWAS results further showcased the enhanced specificity of findings when 632 independent PGS for TUD, SCZ, and BD were compared with transdiagnostic liability. For example, TUD Independent exhibited several associations not observed for the TUD Common 633 634 factor, including ischemic heart disease, atherosclerosis, obesity, and skin conditions. This may 635 reflect a combination of unhealthy lifestyle factors, direct physiological effects of tobacco use, 636 and shared biological pathways underlying these conditions. This finding is also consistent with 637 epidemiologic and genetic research supporting tobacco use as one of the strongest risk factors for cardiovascular disease.<sup>86-88</sup> Differential patterns also emerged for SCZ and BD, with SCZ 638 639 Common and BD Independent showing broader associations with mood disorders than their 640 respective components. Recent research comparing transdiagnostic and disorder-specific genetic 641 effects across 11 psychiatric disorders similarly observed substantial differences in genetic associations,<sup>89</sup> as has research parsing alcohol-specific risk from broader externalizing liability.<sup>90</sup> 642 643 Thus, hierarchical genetic approaches can facilitate a more nuanced understanding of patterns of 644 comorbidity and heterogeneity across co-occurring conditions.

These findings also pave the way for developing more refined PGS than are currently
available. For example, depression PGS show little specificity, accounting for a similar amount
of variance in mood disorders, anxiety disorders, ADHD, and SUDs.<sup>91</sup> Similarly, an evaluation of
16 PGS for psychiatric phenotypes found that most were associated with general
psychopathology rather than the specific domain for which they purported to measure risk.<sup>92</sup>
Although PGS have shown clinical utility in predicting some non-psychiatric disorders,<sup>93,94</sup>

651 prediction performance for psychiatric phenotypes remains limited.<sup>95</sup> This may be due in part to 652 a lack of specificity of currently available psychiatric PGS. Existing PGS are useful for 653 providing a broad overview of genetic predispositions to psychiatric disorders. However, when 654 the focus shifts to exploring associations of a given psychiatric disorder without the confounding 655 influence of co-occurring conditions, a more granular PGS is needed. Efforts to develop more 656 precise PGS, including via the combined application of transdiagnostic and disorder-level 657 genetic methods, may ultimately enhance their clinical utility.

658 Conclusions

Using a combination of multivariate approaches across multiple ancestral groups, we 659 660 examined the common and independent genetic effects on SUDs, psychotic, mood, and anxiety 661 disorders. In doing so, we identified potential biological mechanisms contributing to comorbidity 662 both within and across classes of disorders, while also identifying pathways that may distinguish 663 commonly co-occurring conditions. Isolating transdiagnostic genetic risk factors from those 664 exhibiting greater specificity may aid in enhancing the precision of genetic prediction, as we 665 observed when comparing genetic correlations and phenotypic associations of genetic risk 666 factors. Thus, integrating transdiagnostic and disorder-level genetic models both clarifies the 667 biological underpinnings of psychiatric comorbidity and identifies distinct biological pathways that contribute to heterogeneity within classes of psychiatric conditions. 668

In addition to advancing our understanding of the genetic architecture of SUDs and other
psychiatric disorders, our study also highlights the importance of inclusivity in genetic research.
Previous gSEM studies have been limited to European-ancestry individuals,<sup>16,96,97</sup> but as gSEM
has shown the potential to uncover novel genetic associations and provide greater insights into
the etiology of complex traits and diseases, it is imperative that these advances be made available

- to individuals of all ancestral backgrounds. Unfortunately, in combination with smaller samples,
- 675 lower LD and higher genetic diversity among African-ancestry individuals present statistical
- 676 challenges for many existing analyses.<sup>98</sup> This is further complicated by the high degree of
- 677 admixture present among individuals of non-European ancestries within the United States.<sup>99</sup>
- 678 Accurate consideration of population substructure via the use of large, representative reference
- 679 panels is essential for advancing genetic discovery. We provide details (Supplementary
- 680 Materials) on the efforts we took to ensure the inclusion of African-ancestry individuals despite
- 681 present limitations in the hopes that this may aid researchers faced with similar decisions.
- 682 Advancing genetic discovery across diverse populations will be key in shaping our
- 683 understanding of psychiatric etiology.
- 684

#### 685 Acknowledgements

686 This study is supported by NIH grants K01AA028292 (R.L.K.), R01MH125938 (R.E.P.), 687 P50AA022537 (R.E.P.), T32 HG009495 (K.L.F.), the Brain & Behavior Research Foundation 688 NARSAD grant 28632 PS Fund (R.E.P.), the California Tobacco-Related Disease Research 689 Program (TRDRP; T32IR5226) (S.S-R), the Department of VA Office of Research and 690 Development grants IK2 CX002336 (E.E.H.), I01 BX003341 (H.R.K.) and the Veterans Integrated 691 Service Network 4 Mental Illness Research, Education and Clinical Center. This publication does 692 not represent the views of the Department of VA or the United States Government. We 693 acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the patient-694 participants of Penn Medicine who consented to participate in this research program. We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing 695 696 genetic variant data for analysis. The PMBB is approved under IRB protocol #813913 and 697 supported by the Perelman School of Medicine at the University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National 698 699 Institutes of Health under CTSA award number UL1TR001878.

700

Study	Phenotype	Туре	Cases	Controls	Total
Als et al., 2023, Nature Medicine	MDD	Case-control	387,429	976,554	1,363,98
Otowa et al., 2016, <i>Molecular</i> <i>Psychiatry</i> *	ANX	Case-control	7,016	14,745	21,761
Levey et al., 2020, American Journal of Psychiatry*	ANX	Continuous			175,163
Purves et al., 2020, <i>Molecular</i> <i>Psychiatry</i> *	ANX	Case-Control	25,453	58,113	83,566
Trubetskoy et al., 2022, Nature	SCZ	Case-control	53,386	77,258	130,644
Mullins et al., 2021, <i>Nature</i> <i>Genetics</i>	BD	Case-control	41,917	371,549	413,466
Zhou et al., 2023, <i>Nature</i> <i>Medicine</i>	AUD	Case-control	113,325	639,923	753,248
Levey et al., 2023 <i>Nature</i> <i>Genetics</i>	CanUD	Case-control	42,281	843,744	886,025
Toikumo et al., 2024, <i>Nature</i> <i>Human Behaviour</i>	TUD	Case-control	163,734	331,271	495,005
Kember et al., 2022, <i>Nature</i> <i>Neuroscience</i>	OUD	Case-control	31,473	394,471	425,944
African-Ancestry					
Levey et al., 2021, <i>Nature</i> <i>Neuroscience</i>	MDD	Case-control	25,843	33,757	59,600
Levey et al., 2021, American Journal of Psychiatry	ANX	Continuous			24,448
Bigdeli et al., 2021, Schizophrenia Bulletin	SCZ	Case-control	7,509	8,612	16,121
Bigdeli et al., 2021, Schizophrenia Bulletin	BD	Case-control	3,027	8,097	11,124
Kember et al., 2023, American Journal of Psychiatry	AUD	Case-control	25,012	52,313	77,325
Levey et al., 2023, <i>Nature</i> <i>Genetics</i>	CanUD	Case-control	19,065	104,143	123,208
Toikumo et al., 2024, <i>Nature</i> <i>Human Behaviour</i>	TUD	Case-control	45,465	68,955	114,420
Kember et al., 2022, <i>Nature</i> <i>Neuroscience</i>	OUD	Case-control	8,968	79,530	88,498

#### 701 Table 1. Genome-wide association studies from which summary statistics were obtained.

Bipolar Disorder, AUD = Alcohol Use Disorder, CanUD = Cannabis Use Disorder, TUD = Tobacco Use Disorder, OUD = Opioid Use Disorder. See Supplementary Tables 1-4 for full description of cohorts.

\*Summary statistics were jointly analyzed using MTAG to enhance the statistical power of the ANX phenotype prior to their being used in gSEM (see Supplementary Materials).

703	Figure Legends
704 705 706 707 708	<b>Figure 1. Study schema.</b> FUMA = Functional Mapping and Annotation of GWAS, CTG-VL = Complex Trait Genetics Virtual Lab, LDSC = linkage disequilibrium score regression, PheWAS = phenome-wide association study.
709	Figure 2. Genomic structural equation models. AUD = alcohol use disorder. CanUD =
710 711 712 712	cannabis use disorder, TUD = tobacco use disorder, OUD = opioid use disorder, BD = bipolar disorder, SCZ = schizophrenia, MDD = major depressive disorder, ANX = anxiety, GAD-2 = 2- item GAD questionnaire.
715 714	Figure 3 Manhattan plots for common factors. The substance use disorders factor GWAS
715	identified 143 lead SNPs, the psychotic disorders factor identified 162 lead SNPs, and the
716	mood/anxiety disorders factor identified 112 lead SNPs. The lead SNPs for loci that were not
717 718 719 720	significant in the input GWAS are annotated with yellow diamonds, and lead SNPs for loci not previously significantly associated with phenotypes related to the common factor (i.e., novel) are annotated with green diamonds.
720	Figure 4 Hudson plats and genetic correlations of CWAS-by-subtraction models. The left
722	panel presents Hudson plots and generic correlations of GWAS-by-subtraction models. The ferr
723	for lead SNPs annotated. The right panel presents the genetic correlation results. Independent
724	GWAS refers to the influences on a disorder that do not operate through the common factor,
725	while the Common GWAS refers to influences on the disorder that do operate through the
726	common factor.
727	
728	Figure 5. Genetic correlations for second-order common factors using Complex Trait
729	Genetics Virtual Lab. The dashed line represents the log-transformed Bonferroni-corrected p-
730	value across the 1,437 traits included in the analysis.
731	



#### Figure 2. 736



### 739 **Figure 3.**



740 741





744 F

745

746		References
747 748	1.	Hunt, G.E., Malhi, G.S., Lai, H.M.X. & Cleary, M. Prevalence of comorbid substance use
749		in major depressive disorder in community and clinical settings, 1990–2019: Systematic
750		review and meta-analysis. Journal of Affective Disorders 266, 288-304 (2020).
751	2.	Lai, H.M.X., Cleary, M., Sitharthan, T. & Hunt, G.E. Prevalence of comorbid substance
752		use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic
753		review and meta-analysis. Drug and Alcohol Dependence 154, 1-13 (2015).
754	3.	Hunt, G.E., Malhi, G.S., Cleary, M., Lai, H.M.X. & Sitharthan, T. Comorbidity of bipolar
755		and substance use disorders in national surveys of general populations, 1990–2015:
756		Systematic review and meta-analysis. Journal of Affective Disorders 206, 321-330
757		(2016).
758	4.	European Monitoring Centre for Drugs and Drug Addiction, Domingo-Salvany, A.,
759		Torrens, M. & Mestre-Pintó, J. Comorbidity of substance use and mental disorders in
760		Europe, (Publications Office, 2015).
761	5.	Hunt, G.E., Large, M.M., Cleary, M., Lai, H.M.X. & Saunders, J.B. Prevalence of
762		comorbid substance use in schizophrenia spectrum disorders in community and clinical
763		settings, 1990–2017: Systematic review and meta-analysis. Drug and Alcohol
764		Dependence 191, 234-258 (2018).
765	6.	Horsfall, J., Cleary, M., Hunt, G.E. & Walter, G. Psychosocial treatments for people with
766		co-occurring severe mental illnesses and substance use disorders (dual diagnosis): A
767		review of empirical evidence. Harvard Review of Psychiatry 17, 24-34 (2009).

768	7.	McGovern, M.P., Xie, H., Segal, S.R., Siembab, L. & Drake, R.E. Addiction treatment
769		services and co-occurring disorders: Prevalence estimates, treatment practices, and
770		barriers. Journal of Substance Abuse Treatment 31, 267-275 (2006).
771	8.	Levey, D.F. et al. Reproducible genetic risk loci for anxiety: Results from ~200,000
772		participants in the Million Veteran Program. American Journal of Psychiatry 177, 223-
773		232 (2020).
774	9.	Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in
775		schizophrenia. Nature 604, 502-508 (2022).
776	10.	Mullins, N. et al. Genome-wide association study of more than 40,000 bipolar disorder
777		cases provides new insights into the underlying biology. Nature Genetics 53, 817-829
778		(2021).
779	11.	Kember, R.L. et al. Cross-ancestry meta-analysis of opioid use disorder uncovers novel
780		loci with predominant effects in brain regions associated with addiction. Nature
781		Neuroscience 25, 1279-1287 (2022).
782	12.	Levey, D.F. et al. Multi-ancestry genome-wide association study of cannabis use disorder
783		yields insight into disease biology and public health implications. Nature Genetics
784		(2023).
785	13.	Zhou, H. et al. Multi-ancestry study of the genetics of problematic alcohol use in over 1
786		million individuals. Nature Medicine (2023).
787	14.	Als, T.D. et al. Depression pathophysiology, risk prediction of recurrence and comorbid
788		psychiatric disorders using genome-wide analyses. Nature Medicine 29, 1832-1844
789		(2023).

790	15.	Toikumo, S. et al. Multi-ancestry meta-analysis of tobacco use disorder identifies 461
791		potential risk genes and reveals associations with multiple health outcomes. Nature
792		Human Behaviour (2024).
793	16.	Grotzinger, A.D. et al. Genomic structural equation modelling provides insights into the
794		multivariate genetic architecture of complex traits. Nature Human Behaviour 3, 513-525
795		(2019).
796	17.	Lee, P.H. et al. Genomic relationships, novel loci, and pleiotropic mechanisms across
797		eight psychiatric disorders. Cell 179, 1469-1482.e11 (2019).
798	18.	Grotzinger, A.D. et al. Genetic architecture of 11 major psychiatric disorders at
799		biobehavioral, functional genomic and molecular genetic levels of analysis. Nature
800		<i>Genetics</i> <b>54</b> , 548-559 (2022).
801	19.	Hatoum, A.S. et al. Multivariate genome-wide association meta-analysis of over 1
802		million subjects identifies loci underlying multiple substance use disorders. Nature
803		Mental Health 1, 210-223 (2023).
804	20.	Bhattacharjee, S. et al. A subset-based approach improves power and interpretation for
805		the combined analysis of genetic association studies of heterogeneous traits. American
806		Journal of Human Genetics 90, 821-35 (2012).
807	21.	Schoeler, T. et al. Novel biological insights into the common heritable liability to
808		substance involvement: A multivariate genome-wide association study. Biological
809		<i>Psychiatry</i> <b>93</b> , 524-535 (2023).
810	22.	Demange, P.A. et al. Investigating the genetic architecture of noncognitive skills using
811		GWAS-by-subtraction. Nature Genetics 53, 35-44 (2021).

- 812 23. Waszczuk, M.A. *et al.* Dimensional and transdiagnostic phenotypes in psychiatric
  813 genome-wide association studies. *Molecular Psychiatry* (2023).
- 814 24. Kember, R.L. et al. Genetic underpinnings of the transition from alcohol consumption to
- 815 alcohol use disorder: Shared and unique genetic architectures in a cross-ancestry sample.
- 816 *American Journal of Psychiatry* **180**, 584-593 (2023).
- 817 25. Bigdeli, T.B. et al. Genome-wide association studies of schizophrenia and bipolar
- 818 disorder in a diverse cohort of US veterans. *Schizophrenia Bulletin* **47**, 517-529 (2020).
- 819 26. Otowa, T. *et al.* Meta-analysis of genome-wide association studies of anxiety disorders.
  820 *Molecular Psychiatry* 21, 1391-1399 (2016).
- 821 27. Purves, K.L. *et al.* A major role for common genetic variation in anxiety disorders.
  822 *Molecular Psychiatry* 25, 3292-3303 (2020).
- 823 28. Levey, D.F. et al. Bi-ancestral depression GWAS in the Million Veteran Program and
- 824 meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nature*825 *Neuroscience* 24, 954-963 (2021).
- 826 29. Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics using
  827 MTAG. *Nature Genetics* 50, 229-237 (2018).
- 30. Grotzinger, A.D., Fuente, J.d.l., Privé, F., Nivard, M.G. & Tucker-Drob, E.M. Pervasive
  downward bias in estimates of liability-scale heritability in genome-wide association
- 830 study meta-analysis: A simple solution. *Biological Psychiatry* **93**, 29-36 (2023).
- 831 31. The International HapMap 3 Consortium. Integrating common and rare genetic variation
  832 in diverse human populations. *Nature* 467, 52-8 (2010).
- 833 32. The 1000 Genomes Project Consortium. A global reference for human genetic variation.

834 *Nature* **526**, 68-74 (2015).

- 835 33. Pan-UKB Team. <u>https://pan.ukbb.broadinstitute.org</u>. (2020).
- 836 34. Bates, D. & Maechler, M. Matrix: Sparse and dense matrix classes and methods. *R*
- 837 *package*, <u>http://cran.r-project.org/package=Matrix</u> (2010).
- 838 35. Rosseel, Y. lavaan: An R Package for Structural Equation Modeling. *Journal of Statistical*
- 839 *Software* **48**, 1 36 (2012).
- 840 36. West, S.G., Taylor, A.B. & Wu, W. Model fit and model selection in structural equation
- 841 modeling. in *Handbook of structural equation modeling*. 209-231 (The Guilford Press,
- 842 New York, NY, US, 2012).
- 843 37. Mallard, T.T. et al. Multivariate GWAS of psychiatric disorders and their cardinal
- symptoms reveal two dimensions of cross-cutting genetic liabilities. *Cell Genomics* 2,
  100140 (2022).
- 846 38. Loehlin, J.C. The Cholesky approach: A cautionary note. *Behavior Genetics* 26, 65-69
  847 (1996).
- 848 39. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based
  849 linkage analyses. *American Journal of Human Genetics* 81, 559-575 (2007).
- Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex
  traits. *Nature Genetics* 51, 1339-1348 (2019).
- Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
  annotation of genetic associations with FUMA. *Nature Communications* 8, 1826 (2017).
- de Leeuw, C.A., Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA: Generalized gene-set
  analysis of GWAS data. *PLOS Computational Biology* 11, e1004219 (2015).
- 43. Li, M. *et al.* Integrative functional genomic analysis of human brain development and
  neuropsychiatric risks. *Science* 362, eaat7615 (2018).

- 858 44. The GTEx Consortium *et al.* The GTEx Consortium atlas of genetic regulatory effects
  859 across human tissues. *Science* 369, 1318-1330 (2020).
- Wang, D. *et al.* Comprehensive functional genomic resource and integrative model for
  the human brain. *Science* 362(2018).
- 862 46. Schmitt, Anthony D. *et al.* A compendium of chromatin contact maps reveals spatially
- active regions in the human genome. *Cell Reports* **17**, 2042-2059 (2016).
- 47. Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks
- and functional enrichment analyses for any sequenced genome of interest. *Nucleic Acids*
- 866 *Research* **51**, D638-d646 (2023).
- 867 48. Bulik-Sullivan, B.K. et al. LD Score regression distinguishes confounding from
- polygenicity in genome-wide association studies. *Nature Genetics* **47**, 291-295 (2015).
- 869 49. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.
  870 *Nature Genetics* 47, 1236-1241 (2015).
- 871 50. Cuéllar-Partida, G. *et al.* Complex-Traits Genetics Virtual Lab: A community-driven web
  872 platform for post-GWAS analyses. *bioRxiv*, 518027 (2019).
- 873 51. Brown, Brielin C., Ye, Chun J., Price, Alkes L. & Zaitlen, N. Transethnic genetic-
- 874 correlation estimates from summary statistics. *The American Journal of Human Genetics*875 **99**, 76-88 (2016).
- 876 52. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nature*877 *Genetics* 54, 573-580 (2022).
- 878 53. Verma, A. *et al.* The Penn Medicine BioBank: Towards a genomics-enabled learning
- healthcare system to accelerate precision medicine in a diverse population. *Journal of*
- 880 *Personalized Medicine* **12**, 1974 (2022).

881	54.	Price, A.L. et al. Principal components analysis corrects for stratification in genome-wide
882		association studies. Nature Genetics 38, 904-909 (2006).
883	55.	Galinsky, Kevin J. et al. Fast principal-component analysis reveals convergent evolution
884		of ADH1B in Europe and East Asia. The American Journal of Human Genetics 98, 456-
885		472 (2016).
886	56.	Denny, J.C. et al. Systematic comparison of phenome-wide association study of
887		electronic medical record data and genome-wide association study data. Nature
888		<i>Biotechnology</i> <b>31</b> , 1102-1111 (2013).
889	57.	Sollis, E. et al. The NHGRI-EBI GWAS Catalog: Knowledgebase and deposition
890		resource. Nucleic Acids Research 51, D977-D985 (2023).
891	58.	Araujo, D.J. et al. FOXP1 in forebrain pyramidal neurons controls gene expression
892		required for spatial learning and synaptic plasticity. The Journal of Neuroscience 37,
893		10917-10931 (2017).
894	59.	Braccioli, L. et al. FOXP1 promotes embryonic neural stem cell differentiation by
895		repressing jagged1 expression. Stem Cell Reports 9, 1530-1545 (2017).
896	60.	Ning, Z., Liu, K. & Xiong, H. Roles of BTLA in immunity and immune disorders.
897		Frontiers in Immunology <b>12</b> (2021).
898	61.	Wang, X.D. et al. Nectin-3 links CRHR1 signaling to stress-induced memory deficits and
899		spine loss. Nature Neuroscience 16, 706-13 (2013).
900	62.	Wang, H.L. et al. Prefrontal nectin3 reduction mediates adolescent stress-induced deficits
901		of social memory, spatial working memory, and dendritic structure in mice. Neuroscience
902		Bulletin <b>36</b> , 860-874 (2020).

- 903 63. van der Kooij, M.A. *et al.* Role for MMP-9 in stress-induced downregulation of nectin-3
  904 in hippocampal CA1 and associated behavioural alterations. *Nature Communications* 5,
  905 4995 (2014).
- 906 64. Liu, M. et al. Association studies of up to 1.2 million individuals yield new insights into
- 907 the genetic etiology of tobacco and alcohol use. *Nature Genetics* **51**, 237-244 (2019).
- 908 65. Zhou, H. et al. Genome-wide association study identifies glutamate ionotropic receptor
- 909 GRIA4 as a risk gene for comorbid nicotine dependence and major depression.
- 910 *Translational Psychiatry* **8**, 208 (2018).
- 911 66. Xu, H. et al. Identifying genetic loci and phenomic associations of substance use traits: A
- 912 multi-trait analysis of GWAS (MTAG) study. *Addiction* **118**, 1942-1952 (2023).
- 913 67. Stark, K.L. *et al.* Altered brain microRNA biogenesis contributes to phenotypic deficits in
  914 a 22q11-deletion mouse model. *Nature Genetics* 40, 751-60 (2008).
- 915 68. Wu, Y. et al. Multi-trait analysis for genome-wide association study of five psychiatric
- 916 disorders. *Translational Psychiatry* **10**, 209 (2020).
- 917 69. Charney, A.W. *et al.* Evidence for genetic heterogeneity between clinical subtypes of
- 918 bipolar disorder. *Translational Psychiatry* 7, e993-e993 (2017).
- 919 70. Romero, C. *et al.* Exploring the genetic overlap between twelve psychiatric disorders.
- 920 *Nature Genetics* 54, 1795-1802 (2022).
- 921 71. Martin, E., Schoeler, T., Pingault, J.-B. & Barkhuizen, W. Understanding the relationship
- 922 between loneliness, substance use traits and psychiatric disorders: A genetically informed
- 923 approach. *Psychiatry Research* **325**, 115218 (2023).

- 924 72. Paul, S.E. *et al.* Phenome-wide investigation of behavioral, environmental, and neural
- 925 associations with cross-disorder genetic liability in youth of European ancestry. *medRxiv*,
- 926 2023.02.10.23285783 (2023).
- 927 73. Trelles, M.P. et al. Individuals with FOXP1 syndrome present with a complex
- 928 neurobehavioral profile with high rates of ADHD, anxiety, repetitive behaviors, and
  929 sensory symptoms. *Molecular Autism* 12, 61 (2021).
- 930 74. Drevets, W.C., Wittenberg, G.M., Bullmore, E.T. & Manji, H.K. Immune targets for
- 931 therapeutic development in depression: Towards precision medicine. *Nature Reviews*
- 932 *Drug Discovery* **21**, 224-244 (2022).
- 933 75. Tubbs, J.D., Ding, J., Baum, L. & Sham, P.C. Immune dysregulation in depression:
- 934 Evidence from genome-wide association. *Brain, Behavior, & Immunity Health* 7,
  935 100108 (2020).
- 936 76. Katrinli, S., Oliveira, N.C.S., Felger, J.C., Michopoulos, V. & Smith, A.K. The role of the
- 937 immune system in posttraumatic stress disorder. *Translational Psychiatry* **12**, 313 (2022).
- 938 77. Wang, X.X. *et al.* Nectin-3 modulates the structural plasticity of dentate granule cells and
  939 long-term memory. *Translational Psychiatry* 7, e1228-e1228 (2017).
- 940 78. Parekh, P.K., Johnson, S.B. & Liston, C. Synaptic mechanisms regulating mood state
  941 transitions in depression. *Annual Review of Neuroscience* 45, 581-601 (2022).
- 942 79. Appelbaum, L.G., Shenasa, M.A., Stolz, L. & Daskalakis, Z. Synaptic plasticity and
- 943 mental health: Methods, challenges and opportunities. *Neuropsychopharmacology* **48**,
- 944 113-120 (2023).

945	80.	Marco, E.M.	., Macrì, S. &	z Laviola, G.	Critical age windows	for neurodevelopment	ntal
		,	, ,		<b>L</b> )		

- 946 psychiatric disorders: Evidence from animal models. *Neurotoxicity Research* 19, 286-307
  947 (2011).
- 948 81. Lund, R.J. et al. Placental DNA methylation marks are associated with maternal
- 949 depressive symptoms during early pregnancy. *Neurobiology of Stress* **15**, 100374 (2021).
- 950 82. McGill, M.G. *et al.* Maternal prenatal anxiety and the fetal origins of epigenetic aging.

951 *Biological Psychiatry* **91**, 303-312 (2022).

- 952 83. Jourdon, A., Scuderi, S., Capauto, D., Abyzov, A. & Vaccarino, F.M. PsychENCODE and
- 953 beyond: Transcriptomics and epigenomics of brain development and organoids.
- 954 *Neuropsychopharmacology* **46**, 70-85 (2021).
- 955 84. Kotov, R. et al. Validity and utility of Hierarchical Taxonomy of Psychopathology
- 956 (HiTOP): I. Psychosis superspectrum. *World Psychiatry* **19**, 151-172 (2020).
- 957 85. Sorella, S. et al. Testing the expanded continuum hypothesis of schizophrenia and bipolar
- 958 disorder. Neural and psychological evidence for shared and distinct mechanisms.
- 959 *NeuroImage: Clinical* **23**, 101854 (2019).
- 960 86. Gallucci, G., Tartarone, A., Lerose, R., Lalinga, A.V. & Capobianco, A.M. Cardiovascular

961 risk of smoking and benefits of smoking cessation. *Journal of Thoracic Disease* **12**,

- **962 3866-3876 (2020).**
- 963 87. Rosoff, D.B., Davey Smith, G., Mehta, N., Clarke, T.-K. & Lohoff, F.W. Evaluating the
- 964 relationship between alcohol consumption, tobacco use, and cardiovascular disease: A
- 965 multivariable Mendelian randomization study. *PLOS Medicine* **17**, e1003410 (2020).
- 966 88. Rostron, B.L. et al. Smokeless tobacco use and circulatory disease risk: a systematic
- 967 review and meta-analysis. *Open Heart* 5, e000846 (2018).

968	89.	Keser, E. et al. Isolating transdiagnostic effects reveals specific genetic profiles in
969		psychiatric disorders. medRxiv, 2023.12.20.23300292 (2023).
970	90.	Barr, P.B. et al. Parsing genetically influenced risk pathways: genetic loci impact
971		problematic alcohol use via externalizing and specific risk. Translational Psychiatry 12,
972		420 (2022).
973	91.	Shi, Y. et al. Multi-polygenic scores in psychiatry: From disorder specific to
974		transdiagnostic perspectives. American Journal of Medical Genetics Part B:
975		Neuropsychiatric Genetics 195, e32951 (2024).
976	92.	Neumann, A. et al. Combined polygenic risk scores of different psychiatric traits predict
977		general and specific psychopathology in childhood. Journal of Child Psychology and
978		Psychiatry 63, 636-645 (2022).
979	93.	Khera, A.V. et al. Genome-wide polygenic scores for common diseases identify
980		individuals with risk equivalent to monogenic mutations. Nature Genetics 50, 1219-1224
981		(2018).
982	94.	Inouye, M. et al. Genomic risk prediction of coronary artery disease in 480,000 adults.
983		Journal of the American College of Cardiology 72, 1883-1893 (2018).
984	95.	Lewis, C.M. & Vassos, E. Polygenic scores in psychiatry: On the road From discovery to
985		implementation. American Journal of Psychiatry 179, 800-806 (2022).
986	96.	Grotzinger, A.D. et al. Genetic architecture of 11 major psychiatric disorders at
987		biobehavioral, functional genomic and molecular genetic levels of analysis. Nature
988		Genetics 54, 548-559 (2022).
989	97.	Grotzinger, A.D. et al. Multivariate genomic architecture of cortical thickness and surface
990		area at multiple levels of analysis. Nature Communications 14, 946 (2023).

- 991 98. Bentley, A.R., Callier, S.L. & Rotimi, C.N. Evaluating the promise of inclusion of
- 992 African ancestry populations in genomics. *npj Genomic Medicine* **5**, 5 (2020).
- 993 99. Bick, A.G. et al. Genomic data in the All of Us Research Program. Nature 627, 340-346
- 994 (2024).

995